HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

425(scFv)-ETA'

an anti-EGF receptor immunotoxin

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
- Peptides: 82426
  - Peptide Fragments: 373
    - Immunoglobulin Fragments: 976
      - Immunoglobulin Fab Fragments: 769
        Immunoglobulin Variable Region: 208
        Single-Chain Antibodies: 852
        425(scFv)-ETA': 2

Experts

1.	Barth, Stefan: 2 articles (02/2005 - 10/2003)
2.	Bruell, Daniela: 2 articles (02/2005 - 10/2003)
3.	Bruns, Christiane J: 2 articles (02/2005 - 10/2003)
4.	Finnern, Ricarda: 2 articles (02/2005 - 10/2003)
5.	Fischer, Rainer: 2 articles (02/2005 - 10/2003)
6.	Huhn, Michael: 2 articles (02/2005 - 10/2003)
7.	Ischenko, Ivan: 1 article (02/2005)
8.	Jauch, Karl-Walter: 1 article (02/2005)
9.	Müller, Jürgen: 1 article (02/2005)
10.	Yezhelyev, Maksim: 1 article (02/2005)

Related Diseases

1.	Neoplasms (Cancer) 02/01/2005 - "After intravenous (i.v.) injection of L3.6pl cells into immunodeficient nude mice, both single (20 microg on day 1 after challenge) and repeated (10 microg on days 1, 2, 3 and 4 after tumor cell injection) i.v. administration of 425(scFv)-ETA' resulted in a significant reduction in the average number of lung metastases from 56.25 per animal in the control groups to 0.875 per animal (single injection) and 0.286 per animal (repeated injection), respectively, in the experimental groups. " 02/01/2005 - "In summary, this is the first report showing an in vivo anti-tumor effect caused by the recombinant immunotoxin 425(scFv)-ETA' against disseminated growing metastatic human pancreatic carcinoma cells. " 02/01/2005 - "Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice."
2.	Neoplasm Metastasis (Metastasis) 02/01/2005 - "After intravenous (i.v.) injection of L3.6pl cells into immunodeficient nude mice, both single (20 microg on day 1 after challenge) and repeated (10 microg on days 1, 2, 3 and 4 after tumor cell injection) i.v. administration of 425(scFv)-ETA' resulted in a significant reduction in the average number of lung metastases from 56.25 per animal in the control groups to 0.875 per animal (single injection) and 0.286 per animal (repeated injection), respectively, in the experimental groups. "
3.	Pancreatic Neoplasms (Pancreatic Cancer) 02/01/2005 - "In summary, this is the first report showing an in vivo anti-tumor effect caused by the recombinant immunotoxin 425(scFv)-ETA' against disseminated growing metastatic human pancreatic carcinoma cells. " 02/01/2005 - "Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice." 10/01/2003 - "Finally, 425(scFv)-ETA' showed significant toxicity toward this cell line reaching 50% inhibition of cell proliferation at a concentration (IC50) of 7.5 ng/ml. This is the first report documenting the specific cytotoxicity of a recombinant immunotoxin towards metastatic pancreatic carcinoma cells, suggesting that EGFR-specific antibody toxins may become valuable therapeutic reagents for the treatment of pancreatic carcinoma." 10/01/2003 - "The recombinant anti-EGF receptor immunotoxin 425(scFv)-ETA' suppresses growth of a highly metastatic pancreatic carcinoma cell line."

Related Drugs and Biologics

1.	Immunotoxins (Immunotoxin)
2.	ErbB Receptors (EGF Receptor)
3.	Indicators and Reagents (Reagents)